...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: eGFR and Cognition?
8
Nov 22, 2019 11:47AM
10
Nov 22, 2019 12:28PM
9
Nov 22, 2019 01:10PM
2
Nov 22, 2019 01:49PM
7
Nov 22, 2019 04:05PM
1
Nov 22, 2019 04:22PM
4
Nov 22, 2019 04:38PM
16
Nov 22, 2019 04:47PM
2
Nov 22, 2019 05:10PM
5
Nov 22, 2019 05:16PM
7
Nov 22, 2019 05:21PM
2
Nov 22, 2019 05:34PM
1
Nov 22, 2019 05:58PM
3
Nov 22, 2019 06:19PM
5
Nov 22, 2019 08:14PM
1
Nov 22, 2019 10:29PM
6
Nov 22, 2019 10:48PM
6
Nov 22, 2019 11:19PM
5
Nov 22, 2019 11:43PM
1
Nov 23, 2019 07:08AM
8
Nov 23, 2019 07:20AM
4
Nov 23, 2019 07:23AM
1
Nov 23, 2019 08:05AM
3
Nov 23, 2019 09:06AM
9
Nov 23, 2019 09:24AM
4
Nov 23, 2019 09:58AM
3
Nov 23, 2019 12:31PM
4
Nov 23, 2019 03:28PM
1
Nov 23, 2019 04:31PM
3
Nov 23, 2019 04:49PM

 Yes, it has been discussed a little not a lot. See this message and this message.

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/712700-abca1-overexpression-worsens-colorectal-cancer-prognosis-and-this-can-be-ameliorated-by-apabetalone/messages/2202805#message

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/712700-abca1-overexpression-worsens-colorectal-cancer-prognosis-and-this-can-be-ameliorated-by-apabetalone/messages/2202824#message

On a side note, slide 57 listed a whole bunch of adverse event classes but didn't list any oncology related indications. So the jury is still out on whether there was any effect of apabetalone on cancer, including colorectal cancer. Sometimes, clinical trials have surprise benefits. Just recently, CANTOS cardiovascular outcomes trial for Novartis's anti-IL-1B antibody canakinumab found significantly less lung cancer in the patients treated w/ canakinumab. So there may be surprises yet to come with BETonMACE.

https://www.thelancet.com/journals/lancet/article/PIIS0140-67361732247-X/fulltext

As another side note, looks like Novartis is gearing up for a $7 billion buyout of The Medicine's Company for the inclisiran PCSK9 RNAi drug. $85 per share for MDCO is the rumor (not finalized yet). Article says deal is worth close to $10 billion using a fully diluted share count. And this is without a completed CVOT or approved drug. The MDCO Orion LDL-C Phase 3 lowering program just wrapped up and NDA/MAA applications to FDA/EMA havne't even been submitted yet.

https://www.wsj.com/articles/novartis-nears-deal-to-buy-cholesterol-drug-maker-medicines-co-11574535418

BDAZ

 

6
Nov 23, 2019 06:16PM
4
Nov 23, 2019 06:55PM
5
Nov 23, 2019 06:59PM
2
Nov 23, 2019 07:11PM
9
Nov 23, 2019 08:15PM
6
Nov 23, 2019 09:19PM
4
Nov 25, 2019 01:39AM
3
Nov 25, 2019 02:14AM
2
Nov 25, 2019 02:16AM
5
Nov 25, 2019 02:40AM
2
Nov 25, 2019 02:48AM
1
Nov 25, 2019 08:03AM
5
Nov 25, 2019 09:17AM
3
Nov 25, 2019 10:20AM
5
Nov 25, 2019 02:39PM
Share
New Message
Please login to post a reply